Pharmacokinetic studies of 68Ga-labeled bombesin (68Ga-BZH3) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results
Purpose: - Dynamic PET studies with a 68Ga-Bombesin analog, the 68Ga-BZH3, were performed in patients with highly suspected recurrent gliomas to investigate the effect of the receptor scintigraphy on tumor grading. Furthermore, dynamic F-18 Fluorodeoxyglucose (FDG) studies were performed fo...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 2011
|
| In: |
Clinical nuclear medicine
Year: 2011, Volume: 36, Issue: 2, Pages: 101-108 |
| ISSN: | 1536-0229 |
| DOI: | 10.1097/RLU.0b013e318203bb24 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/RLU.0b013e318203bb24 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/nuclearmed/Fulltext/2011/02000/Pharmacokinetic_Studies_of_68Ga_Labeled_Bombesin.4.aspx 
|
| Author Notes: | Antonia Dimitrakopoulou-Strauss, Marcel Seiz, Jochen Tuettenberg, Kirsten Schmieder, Michael Eisenhut, Uwe Haberkorn, and Ludwig G. Strauss |
| Summary: | Purpose: - Dynamic PET studies with a 68Ga-Bombesin analog, the 68Ga-BZH3, were performed in patients with highly suspected recurrent gliomas to investigate the effect of the receptor scintigraphy on tumor grading. Furthermore, dynamic F-18 Fluorodeoxyglucose (FDG) studies were performed for comparison. - Methods: - The study consisted of 15 patients with histologically confirmed recurrent gliomas. Dynamic PET scans using 68Ga-BZH3 and FDG were obtained on 2 different days within 1 week. Multivariate analysis was used for the evaluation of the kinetic data. Standardized uptake values were calculated and a compartment (2-tissue) as well as a noncompartment model was used for data evaluation of both tracers. - Results: - The evaluation includes 6 patients with a WHO II, 6 patients with a WHO III, and 3 patients with a WHO IV recurrent gliomas. Of the 15 patients, 10 patients demonstrated an increased 68Ga-BZH3 uptake visually, 3 of them with a WHO II, 4 with a WHO III, and 3 with a WHO IV tumor. Of the 15 patients, 6 patients revealed an enhanced FDG metabolism visually, 3 of them with a WHO II, and 3 with a WHO III. None of the 3 patients with WHO IV tumor demonstrated an enhanced FDG-uptake. Discriminant analysis based on a combination of FDG influx and binding potential of 68Ga-BZH3 best discriminated between low- and high-grade gliomas with a correct classification rate of 100%. - Conclusions: - 68Ga-BZH3 seems to be helpful in patients with recurrent gliomas for the differentiation between low- and high-grade gliomas. Overall, the quantitative evaluation was superior to the visual analysis and the parameters of the 68Ga-BZH3 kinetics were more helpful than those of FDG for the differentiation between low- and high-grade gliomas. |
|---|---|
| Item Description: | Im Titel ist "68" bei "Ga" hochgestellt Im Titel ist "3" bei "68Ga-BZH" tiefgestellt Gesehen am 13.06.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1536-0229 |
| DOI: | 10.1097/RLU.0b013e318203bb24 |